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Abstract
Mammalian gene regulation is dependent on tissue-specific enhancers that can act across large 
distances to influence transcriptional activity1-3. Mapping experiments have identified hundreds of 
thousands of putative enhancers whose functionality is supported by cell type–specific chromatin 
signatures and striking enrichments for disease-associated sequence variants4-11. However, these 
studies did not address the in vivo functions of the putative elements or their chromatin states and 
could not determine which genes, if any, a given enhancer regulates. Here we present a strategy to 
investigate endogenous regulatory elements by selectively altering their chromatin state using 
programmable reagents. Transcription activator–like (TAL) effector repeat domains fused to the 
LSD1 histone demethylase efficiently remove enhancer-associated chromatin modifications from 
target loci, without affecting control regions. We find that inactivation of enhancer chromatin by 
these fusion proteins frequently causes down-regulation of proximal genes, revealing enhancer 
target genes. Our study demonstrates the potential of ‘epigenome editing’ tools to characterize an 
important class of functional genomic elements.
Here we sought to develop a strategy for testing the functions of genomic elements and 
associated chromatin states in their endogenous context. We focused on active enhancers, 
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which are marked by histone H3 K4 mono- and di-methylation (H3K4me1 and H3K4me2) 
and K27 acetylation (H3K27ac)4,6,9,12,13. We hypothesized that a given enhancer could be 
inactivated by removal of these chromatin marks. To test this hypothesis, we engineered 
monomeric fusions between TAL effector repeat arrays and the lysine-specific demethylase 
1 (LSD1)14. TAL effector repeats are modular DNA-binding domains that can be designed 
to bind essentially any genomic sequence of interest15,16. LSD1 catalyzes the removal of H3 
K4 and H3 K9 methylation1-3,14. Although prior studies have used TAL effector nucleases 
to edit specific genomic regions to disrupt coding sequences4-11,17,18, we reasoned that TAL 
effector-LSD1 fusions could provide a more versatile means for modulating the activity of 
noncoding elements and evaluating the significance of their chromatin states.
We initially focused on a candidate enhancer in the stem cell leukemia (SCL) locus that is 
enriched for H3K4me2 and H3K27ac in K562 erythroleukemia cells4,6,9,12,13,19. SCL 
encodes a developmental transcription factor with critical functions in hematopoiesis that is 
expressed in K562 cells. We designed a TAL effector array to bind an 18 base sequence in a 
segment of this enhancer predicted to be nucleosome-free based on DNase hypersensitivity 
(Fig. 1A, see Methods). As the binding specificity of monomeric TAL effectors has yet to 
be thoroughly characterized, we first created an expression construct encoding this TAL 
effector array fused to a 3X FLAG epitope. We transfected this construct into K562 cells, 
confirmed expression by Western blot, and mapped genome-wide binding by chromatin 
immunoprecipitation and sequencing (ChIP-seq). We found that the top ranked binding site 
corresponds precisely to the target sequence within the SCL locus (Figure 1B, 
Supplementary Fig. 1). We did not identify any other ChIP-seq peaks that were reproducibly 
detected in the two biological replicates. We also scanned the genome for sequence motifs 
with one or two mismatches from the TAL effector recognition motif, but did not detect any 
significant ChIP-seq enrichments at these sites either (Supplementary Fig. 1). These data 
support the specificity of TAL effector binding and are consistent with prior demonstrations 
of TAL effector activator domain fusions that selectively induce target genes14,18,20.
To modulate chromatin state at the SCL enhancer, we combined the corresponding TAL 
effector with the LSD1 demethylase. We transfected K562 cells with a construct encoding 
this TAL effector-LSD1 (TALE-LSD1) fusion or a control mCherry vector, cultured the 
cells for three days and measured histone modification levels by ChIP-qPCR. We found that 
the fusion reduced H3K4me2 signals at the target locus by ~3-fold relative to control, but 
had no effect at several non-target control enhancers (Fig. 1C, Supplementary Fig. 2). In 
addition to its enzymatic activity, LSD1 physically interacts with other chromatin modifying 
enzymes, including histone deacetylases21. We therefore also tested for changes in 
H3K27ac, another characteristic enhancer mark. We found that the fusion reduced H3K27ac 
levels by >4-fold, suggesting that LSD1 recruitment leads to generalized chromatin 
inactivation at the target enhancer.
To eliminate the possibility that the chromatin changes reflect displacement of other 
transcription factors by the TAL effector, we tested a construct encoding the TAL effector 
without LSD1. We also examined a TALE-LSD1 fusion with a scrambled target sequence 
not present in the human genome to control for non-specific effects of LSD1 
overexpression. Neither construct altered H3K4me2 or H3K27ac levels at the SCL locus 
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(Fig. 1C, Supplementary Fig. 3). Lastly, to evaluate the specificity of the fusion 
comprehensively, we used ChIP-seq to map H3K4me2 and H3K27ac genome-wide in 
TALE-LSD1 and control transfected K562 cells. These data confirmed loss of H3K4me2 
and H3K27ac across a 2 kb region surrounding the target sequence within the SCL locus 
(Fig. 1D).
These results indicate that directed LSD1 recruitment results in locus-specific reduction of 
H3K4me2 and H3K27ac. The generalized effect on chromatin state may be a direct 
consequence of H3K4 demethylation or, alternatively, may depend on partner proteins that 
associate with LSD115,16,22,23. Regardless, prior studies indicate that sequence elements 
enriched for H3K4me2 and H3K27ac exhibit enhancer activity in corresponding cell types, 
whereas elements lacking these marks are rarely active4,6,12. Hence, our results suggest that 
this TALE-LSD1 fusion efficiently and selectively inactivates its target enhancer.
We therefore expanded our study to investigate a larger set of candidate enhancers with 
active chromatin in K562 cells. These include nine elements in developmental loci, sixteen 
additional highly cell type-specific elements, and fifteen intergenic elements. We designed 
and produced TALE repeat arrays for sequences in these 40 enhancers using the Fast 
Ligation-based Automatable Solid-phase High-throughput (FLASH) assembly 
method24(Supplementary Table 1). We then cloned LSD1 fusion constructs for each TALE 
and transfected them individually into K562 cells, alongside mCherry control plasmid 
transfected separately into cells. At three days post transfection, we measured H3K4me2 and 
H3K27ac by ChIP-qPCR using two primer sets per target enhancer. We found that 26 of the 
40 TALE-LSD1 constructs (65%) substantially reduced levels of these modifications at their 
target loci, relative to control transfected cells (Fig. 2; see Methods). An additional 8 
constructs caused more modest reductions at their targets, suggesting that the strategy can be 
effective at most enhancers (Fig. 2). ChIP-qPCR measurements of H3K4me1 and H3K4me3 
confirm that the reagents also reduce these alternative H3K4 methylation states 
(Supplementary Fig. 4). The induced changes were specific to the target loci, as analogous 
measurements at non-target enhancers did not reveal substantial changes (Supplementary 
Fig. 5). Furthermore, genome-wide ChIP-seq analysis of two TALE-LSD1 fusions that were 
positive by ChIP-qPCR confirmed the robustness and specificity with which they reduce 
chromatin signals at target loci (Supplementary Fig. 6).
We next considered whether reduced chromatin activity at specific enhancers affects the 
transcriptional output of nearby genes. We initially focused on 9 TALE-LSD1 fusions that 
robustly alter chromatin state (Fig. 2), and systematically screened for regulated genes using 
a modified RNA-seq procedure termed 3′ Digital Gene Expression (3′DGE). By only 
sequencing the 3′ ends of mRNAs, this procedure enables quantitative analysis of transcript 
levels at modest sequencing depths25 (Garber M., manuscript in review). We transfected the 
9 TALE-LSD1 constructs individually into K562 cells, alongside with control mCherry 
plasmids and measured mRNA levels in biological replicate. We normalized each 3′DGE 
dataset based on a negative binomial distribution and excluded any libraries that did not 
satisfy quality controls (see Methods)26. We then examined whether any of the TALE-
LSD1 reagents substantially altered the expression of genes in the vicinity of its target 
enhancer. Four of the nine tested fusions (44%) caused a nearby gene to be down-regulated 
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by at least 1.5-fold, with both biological replicates for the tested fusion exhibiting larger 
expression change than any of the other effectors or controls (see Methods, Fig. 3A, 
Supplementary Fig. 7).
The significance of these transcriptional changes is supported by a simulated analysis of a 
random sampling of 1000 genomic locations that did not yield any false-positives in which 
an adjacent gene scored as regulated (FDR<0.1%). The expression changes were also 
confirmed by quantitative RT-PCR (Supplementary Fig. 8). Two of the enhancers that 
significantly regulated genes are intergenic, wheras a third coincides with the 3′ end of a 
gene, but affects the activity of the next downstream gene. The fourth scoring enhancer 
resides in the first intron of ZFPM2. We confirmed that ZFPM2 down-regulation requires 
LSD1 recruitment, as a TALE lacking the demethylase did not affect its expression 
(Supplementary Fig. 8). We cannot distinguish whether the other five putative enhancers 
have weak transcriptional effects below our detection threshold or, alternatively, do not 
regulate any genes in K562 cells. Regardless, our results indicate that TALE-LSD1 fusions 
can alter enhancer activity in a targeted, loss-of-function manner, and thereby enable 
identification and modulation of their target genes.
The high prevalence of putative enhancers in the genome suggests that many act redundantly 
or function only in specific contexts, which could explain our inability to assign target genes 
to roughly half of the tested elements. To address the former, we examined three putative 
enhancers within the developmental locus encoding ZFPM2 (Fig. 3B). In addition to the 
TALE-LSD1 fusion targeted to the intronic enhancer described above (Fig. 3A, 3B; 
enhancer +10), we designed and validated TALE-LSD1 fusions that reduced modification 
levels at two additional intronic ZFPM2 enhancers (enhancers +16, +45) (Fig. 2, 3B). First, 
we transfected each TALE-LSD1 fusion individually and tested their effects on ZFPM2 
expression by qPCR. Whereas the fusion targeting the original +10 enhancer reduced 
ZFPM2 expression by ~2-fold, the fusions targeting the +16 and +45 enhancers showed only 
modest reductions of ~13% and ~22%, respectively, that did not reach statistical 
significance (Fig. 3C). To determine if these enhancers act additively or synergistically, we 
transfected the fusions in pairwise combinations. Although targeting pairs of enhancers 
tended to reduce gene expression more than hitting a single enhancer, the cumulative effects 
were substantially less than the sum of the two individual effects. This suggests that the 
multiple enhancers in this locus function redundantly to maintain ZFPM2 expression in 
K562 cells. These results indicate the potential of programmable TALE-LSD1 fusions to 
shed light on complex regulatory interactions among multiple enhancers and genes in a 
locus.
In conclusion, our study presents epigenome editing tools to modulate the activity of a 
poorly characterized class of functional genomic elements in their native contexts. The 
approach should also be useful for directing alterations of other epigenomic features, 
including repressive chromatin states and potentially with temporal control27. We 
demonstrate that programmable TALE-LSD1 fusions can be used to modulate the chromatin 
state and regulatory activity of individual enhancers with high specificity. These reagents 
should be generally useful for evaluating candidate enhancers identified in genomic 
mapping studies with higher throughput than direct genetic manipulations, particularly when 
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combined with high-throughput methods for engineered TAL effector-based proteins24. 
Moreover, the approach may allow researchers to modulate developmental or disease-
associated genes in specific contexts by inactivating their tissue-specific enhancers, and thus 
ultimately yield new therapeutic strategies.
Online Methods
Construction of TAL effector fusions
The open reading frame for LSD1 was amplified from a cDNA library from K562 cells 
using the following primers (F:gttcaagatctttatctgggaagaaggcgg, 
R:gaccttaattaaatgggcctcttcccttagaa). The PCR product was cloned into a TAL effector 
compatible expression vector28 using PacI and BamHI/BglII such that LSD1 is fused to the 
C-terminal end of the TAL effector. TAL effector repeat array monomers were designed and 
assembled using FLASH as described24. These assembled DNA fragments were cloned into 
the expression vector using BsmBI sites and verified by restriction enzyme digestion and 
sequencing. The mCherry control vector was created by incorporating an mCherry open 
reading frame in place of the TAL effector array using NotI and PacI. Control TAL effector 
vectors lacking LSD1 were constructed using BamHI and PacI to remove LSD1, followed 
by blunt end ligation. The 3X Flag Tagged TAL effector vector was created by designing a 
gBlock (IDT) encoding a 29 amino acid Glycine:Serine linker followed by the 3X Flag 
sequence and cloning into the BamHI and PacI sites at the C-terminal end of the TAL 
effector repeat. Plasmids for construction of LSD1 and 3X Flag fusions will be available 
from Addgene.
Cell culture and transfection
The human erythroleukemia cell line, K562 (ATCC, CLL-243), was cultured in RPMI with 
10% FBS, 1% Pen/Strep (Life Technologies). For transfections, 5 × 10^6 cells per 
transfection were washed once with PBS. Cells were then transfected with 20 ug of TAL 
effector plasmid DNA or control mCherry plasmid by nucleofection with Lonza Kit V, as 
described by the manufacturer (Program T-016). Cells were immediately resuspended in 
K562 media at a density of 0.25 × 10^6 cells/ml. Cells were harvested at 72 hours for ChIP 
or RNA extraction. For ZFPM2 gene expression analysis, we standardized the total amount 
of DNA per transfection by co-transfecting either 10ug of a single TALE-LSD1 plasmid 
plus 10 ug of a scrambled TALE-LSD1 plasmid, or 10ug each of two TALE-LSD1 
plasmids. Transfection efficiency, determined by flow cytometry analysis of mCherry 
control transfected cells, ranged from 89-94% across multiple biological replicates.
Flag tagged ChIP
TALE-3X Flag transfected K562 cells were crosslinked with 0.5% formaldehyde for 5 
minutes at room temperature. Nuclei were isolated and lysed as described29. After 
sonication, solubilized chromatin was incubated with protein G Dynabeads (Invitrogen) and 
0.5 ug anti-FLAG M2 antibody (Sigma) at 4C overnight. Samples were washed with TBS-T, 
low salt (150 mM NaCl, 2mM Tris-HCl, 1% Triton-X), LiCl (250mM LiCl, 1mM Tris-HCl, 
1% Triton-X), and high salt (750mM NaCl, 2 mM Tris-HCl, 1% Triton-X) buffers at room 
temperature. Enriched chromatin was eluted (1% SDS, 5mM DTT) at 65 C for 20 minutes, 
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purified and used directly for Illumina library prep. A control library was made from input 
DNA diluted to 50 picograms. Reads were aligned using Bowtie, and peak analysis was 
done using MACS with input controls, and masking genomic regions repetitive in Hg19 or 
K56230.
Native ChIP
Quantitative measurements of histone modification levels were preformed in parallel using 
native ChIP. 0.01 U of MNase (ThermoScientific) was added to 1 ml lysis buffer (50mM 
Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.1% sodium deoxycholate, 1mM CaCl2) with 
EDTA free proteinase inhibitor. For each transfected sample, 260 ul of MNase:Lysis buffer 
was added and incubated for 15 minutes at 25 C, and 20 minutes at 37C. MNase was 
inactivated by adding 20 mM EGTA. The lysed sample was split into 96 well plate format 
for ChIP with H3K4me2 (abcam ab32356), H3K27ac (Active Motif 39133), H3K4me3 
(Abcam ab8580), or H3K4me1 (Abcam ab8895). Antibody binding, bead washing, DNA 
elution and sample clean-up were performed as described31. ChIP DNA was analyzed by 
real-time PCR using FastStart Universal SYBR Green Master (Applied Biosystems), and 
enrichment ratios were calculated relative to equal amount of input DNA. Enrichment was 
normalized across ChIP samples to two standard off-target control enhancers 
(Supplementary Table 2), and fold-ratios were calculated relative to mCherry plasmid 
transfected cells assayed in parallel. Each TAL effector ChIP experiment was performed in a 
minimum of 3 biological replicates. TAL effector-LSD1 reagents were scored based on the 
fold-changes of H3K4me2 and H3K27ac for two primers flanking the target sequence. A 
given reagent was scored ‘positive’ if it induced a 2-fold or greater reduction in modification 
signal for at least 2 of these 4 values, with a p-value<0.05 using a one-tailed t-test. For 
ChIP-seq maps, 5 ng of ChIP DNA was used for library preparation as described31.
Gene expression analysis
Genome-wide RNA expression analysis was performed using 3′DGE RNA-seq. Total RNA 
from 1 million TALE-LSD1 transfected or control (K562 alone or mCherry plasmid 
transfected) cells in biological replicate using RNeasy Mini kit (Qiagen). 2 ug of total RNA 
was fragmented and the 3′ ends of polyA mRNAs were isolated using Dynabeads 
(Invitrogen), and used to generate Illumina sequencing libraries, as described25. To precisely 
quantify the gene expression, we used a 3′ DGE analysis pipeline (Garber M., in 
preparation, http://garberlab.umassmed.edu/software/esat/). The pipeline estimates gene 
expression based on the maximum number of reads in any 500 basepair window within 10 
kb of the annotated 3′ gene end. This approach compensates for the fact that annotated ends 
for some genes are imprecise and may be cell type dependent and yields accurate 
quantifications. We then normalized the gene expression levels, scaling samples by the 
median gene inter-sample variation, as described in26. This approach controls for differences 
in sequencing depth between libraries and in the overall transcript abundance distribution. 
We excluded libraries with extreme normalization coefficients below 0.7 or above 1.5. To 
identify candidate regulated genes, we examined the three closest upstream and three closest 
downstream genes. We scored a gene as regulated if (i) it was detected in control K562 cells 
with a normalized RNA-seq value >10, i.e. the top 50th percentile of expression; (ii) its 
mean expression value was at least 1.5-fold lower in the corresponding on-target TALE-
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LSD1 libraries compared to all other libraries, p < 0.05 calculated using DESeq26 and (iii) 
its normalized 3′DGE values in the on-target TALE-LSD1 libraries were the two lowest 
over all 22 datasets. To simulate the 1000 random binding sites, we sample genomic 
positions uniformly at random and use rejection sampling to ensure that the random set has a 
similar distribution relative to genomic annotations (intergenic, promoter, gene body, UTR) 
to the actual TAL effector binding sites. We then used significance testing criteria identical 
to that applied to the actual TAL effector experiments.
For RT-PCR based expression analysis, total RNA was extracted and reverse transcribed 
into cDNA using Superscript III First-Strand Synthesis system for RT-PCR (Invitrogen). 
Quantitative PCR was performed with FastStart Universal SYBR Green Master (Invitrogen) 
with primer sequences listed in Table S2 on an ABI 7500 machine. Gene expression values 
are presented as log2 Ct ratios relative to 2 housekeeping control genes (TBP and SDHA), 
and represents an average of four independent biological replicates each assayed in two 
technical replicates.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Programmable TALE-LSD1 fusion modulates chromatin at an endogenous enhancer. (a) 
Schematic depicts workflow for identification of nucleosome-free target sequence (black 
stripe) within enhancer (blue peaks of histone modification) and design of corresponding 
TAL effector fusion. TAL effector arrays comprising ~18 repeats (colored ovals) that each 
bind a single DNA base are fused to the LSD1 histone H3K4 demethylase. Upon transient 
transfection, we assayed for binding to the target site, induced chromatin changes and 
altered gene expression. (b) ChIP-seq signal tracks show H3K4me2, H3K27ac and TALE 
binding in K562 cells across a targeted enhancer in the SCL locus. Control tracks show anti-
FLAG ChIP-seq signals in mCherry transfected cells and input chromatin. The target 
sequence of the TALE is indicated below. (c) ChIP-qPCR data show fold-change of 
H3K4me2 and H3K27ac enrichment in cells transfected with constructs encoding TALE-
LSD1, the same TALE but lacking LSD1, or a ‘non-target’ TALE-LSD1 whose cognate 
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sequence is not present in the human genome. Data are presented as log2 ratios normalized 
to mCherry plasmid transfected control (error bars represent ±s.e.m. n=4 biological 
replicates). (d) ChIP-seq tracks show H3K4me2 and H3K27ac signals across the target SCL 
locus for K562 cells transfected with TAL effector-LSD1 or control mCherry plasmid.
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TALE-LSD1 fusions targeting 40 candidate enhancers in K562 cells. The FLASH assembly 
method was used to engineer 40 TALE-LSD1 fusions that recognize 17 – 20 base sequences 
in nucleosome-free regions of candidate enhancers. These reagents were transfected into 
K562 cells and evaluated by ChIP-qPCR. Bi-directional plot shows fold change of 
H3K4me2 (green, left) and H3K27ac (blue, right) at the target locus for each of the 40 
fusions, which are ordered by strength of effect and labeled by their target genomic site. 
Most target sites were evaluated using two qPCR primer sets. Data are presented as log2 
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ratios normalized to mCherry plasmid transfected control (error bars represent ±s.e.m., n=3 
biological replicates). The solid red lines define a 2-fold difference (log2 = −1). The dashed 
red line demarcates constructs that induce a 2-fold reduction in histone modification levels 
for two or more of the four values shown. Regulated genes for 9 tested fusions are shown at 
right (see text and Figure 3). The data indicate that TALE-LSD1 reagents provide a general 
means for modulating chromatin state at endogenous enhancers.
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TALE-LSD1 fusions to endogenous enhancers affect proximal gene expression. (a) Nine 
TALE-LSD1 fusions that robustly alter chromatin state (see Figure 2) were evaluated for 
their effects on gene expression by RNA-seq (see Methods). For each of the nine fusions, a 
bar graph shows normalized gene expression values for the closest expressed upstream and 
downstream genes. The red and pink bars indicate the gene expression value for two 
biological replicates in cells transfected with the corresponding ‘on-target’ TALE-LSD1 
construct, and the black bars indicate the mean expression in cells transfected with control 
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‘off-target’ TALE constructs (error bars for the “Control” represent s.e.m, n=20 non-target 
libraries, see Methods, * indicates p <0.05 using an unpaired t-test). (b) ChIP-seq tracks 
show H3K4me2 and H3K27ac signals across the Zfpm2 locus. TAL effector-LSD1 fusions 
were designed to target candidate enhancers (black bars) in the first intron. (c) Bar graph 
shows relative ZFPM2 expression in K562 cells transfected with the indicated combinations 
of TALE-LSD1 constructs. Error bars indicate ±s.e.m of 4 RT-qPCR measurements). The 
data suggest that these enhancers act redundantly in K562 cells to maintain ZFPM2 
expression.
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